Oncology · Colorectal Cancer
The identification of MBD2's role in silencing SFRP1 presents a significant opportunity for developing novel therapeutic strategies in colorectal cancer. This could reshape treatment paradigms and enhance competitive positioning for companies focused on oncology.
Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.
Last run 6/30/2026, 12:35:00 AM
Assessment confidence: 63% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.
The identification of MBD2's role in silencing SFRP1 presents a significant opportunity for developing novel therapeutic strategies in colorectal cancer. This could reshape treatment paradigms and enhance competitive positioning for companies focused on oncology. Regulatory context from FDA (Sunscreen: How to Help Protect Your Skin from the Sun) supports the near-term read. Assessment grounded in 8 ranked evidence items (3 high-relevance).
Portfolio teams should explore MBD2 and SFRP1 as potential targets for novel CRC therapies, enhancing competitive positioning. The strongest clinical anchor is A Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancers (ClinicalTrials.gov), sub-indication match (colorectal cancer). New therapeutic targets like MBD2 and SFRP1 could lead to innovative treatments, potentially increasing market share in the colorectal cancer segment.
The most relevant competitive pressure comes from Understanding the mechanism of SFRP1 silencing may lead to new therapeutic strategies in CRC, impacting current treatment paradigms..
Regulatory risk is concentrated around If new therapies targeting these mechanisms are developed, they may require regulatory approval, impacting timelines for market entry and compliance..
Sunscreen: How to Help Protect Your Skin from the Sun
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceWithdrawn | Cancer Accelerated Approvals
FDAlow relevance
Regulatory pathway relevance (approval); Broad oncology match without sub-indication specificity
FDA document
View sourceOngoing | Cancer Accelerated Approvals
FDAlow relevance
Regulatory pathway relevance (approval); Broad oncology match without sub-indication specificity
FDA document
View sourceOncology (Cancer)/Hematologic Malignancies Approval Notifications
FDAlow relevance
Regulatory pathway relevance (approval); Broad oncology match without sub-indication specificity
FDA document
View sourceA Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancers
ClinicalTrials.govhigh relevance
Sub-indication match (colorectal cancer)
FDA document
View sourceCadonilimab for PD-1/PD-L1 Blockade-refractory, MSI-H/dMMR, Advanced Colorectal Cancer
ClinicalTrials.govhigh relevance
Sub-indication match (colorectal cancer)
FDA document
View sourcePrognostic Role of Inhibitor of Apoptosis Protein Overexpression on Recurrence Rate in Cervical Cancer
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceComparing Cisplatin Every Three Weeks to Cisplatin Weekly When Combined With Radiation for Patients With Advanced Head and Neck Cancer
ClinicalTrials.govlow relevance
Broad oncology match without sub-indication specificity
FDA document
View sourceSEC61G identified as a pan-cancer biomarker and potential therapeutic target
Humanexa Signalslow relevance
Broad oncology match without sub-indication specificity
MBD2 suppresses SFRP1 expression and promotes colorectal cancer development by blocking MED19 binding to its methylated promoter.
PubMedhigh relevance
Sub-indication match (colorectal cancer); Entity match (mbd2)
FDA document
View sourceThe "oral-gut axis" transmission of microorganisms in colorectal cancer: Insights from Peptostreptococcus' perspective.
PubMedmedium relevance
Sub-indication match (colorectal cancer)
FDA document
View sourceADAR1-circRAB5A-BIP axis governs radiotherapy resistance in colorectal cancer through coordinating protective autophagy and apoptosis.
PubMedmedium relevance
Sub-indication match (colorectal cancer)
FDA document
View sourcem6A methylation of circKPNA2 promotes colorectal carcinogenesis by activating the RIN1-Ras pathway.
PubMedmedium relevance
Sub-indication match (colorectal cancer)
FDA document
View sourceLidocaine enhances antitumor effects of sorafenib and GW5074 in colorectal cancer cells.
PubMedmedium relevance
Sub-indication match (colorectal cancer)
FDA document
View sourceGut microbiota and diet in colorectal cancer: Converging determinants of carcinogenesis.
PubMedmedium relevance
Sub-indication match (colorectal cancer)
FDA document
View sourceULK1's role in cancer progression and its emerging therapeutic potential.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceAdvances in SEC61G research: from ER translocon subunit to emerging pan-cancer oncogenic roles.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourcePrecedents · guidance
Loading regulatory precedents…
View full regulatory analysisCompetitors · threats
Loading competitive findings…
View full competitive analysisThe identification of MBD2's role in silencing SFRP1 presents a significant opportunity for developing novel therapeutic strategies in colorectal cancer. This could reshape treatment paradigms and enhance competitive positioning for companies focused on oncology.
New therapeutic targets like MBD2 and SFRP1 could lead to innovative treatments, potentially increasing market share in the colorectal cancer segment.
If new therapies targeting these mechanisms are developed, they may require regulatory approval, impacting timelines for market entry and compliance.
Monitor developments in therapeutic strategies targeting MBD2 or SFRP1 in CRC and related clinical trials.
Track for follow-up milestones; no immediate action required.